Anteris Technologies Global (ASX:AVR) Research & Development: A$104.83 Mil (TTM As of Mar. 2026)


ASX:AVR Anteris Technologies Global Corp ASX:AVR
50 GF Score
Price A$15.00
! 7 Warning Signs
View Full Analysis

What is Anteris Technologies Global Research & Development?

Anteris Technologies Global ASX:AVR +10.05% 50 Research & Development is A$104.83 Mil as of Mar. 2026. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Anteris Technologies Global's Research & Development for the three months ended in Mar. 2026 was A$24.88 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was A$104.83 Mil.

Anteris Technologies Global  (ASX:AVR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Anteris Technologies Global Research & Development Related Terms

Anteris Technologies Global Research & Development Historical Data

* Premium members only.

The historical data trend for Anteris Technologies Global's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anteris Technologies Global Research & Development Chart

Anteris Technologies Global Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.12 13.32 23.26 81.24 104.03

Anteris Technologies Global Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.12 25.10 25.48 29.37 24.88
ASX:AVR
50GF Score
Anteris Technologies Global Corp ASX:AVR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anteris Technologies Global Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$104.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$104.83 Mil mean?
Anteris Technologies Global (ASX:AVR) has a Research & Development of A$104.83 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Anteris Technologies Global and its competitors.
Is Anteris Technologies Global's Research & Development too high?
Anteris Technologies Global's current Research & Development is A$104.83 Mil. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's Research & Development compare to INMD and QDEL?
Anteris Technologies Global's Research & Development of A$104.83 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Anteris Technologies Global and its competitors. Anteris Technologies Global's current Research & Development is A$104.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current Research & Development of A$104.83 Mil. The current Research & Development is A$104.83 Mil. Anteris Technologies Global's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current Research & Development is A$104.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anteris Technologies Global Business Description

Other Exchanges AVR:USA
Address 9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score

Get the complete analysis for ASX:AVR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$15.00
Price